摘要
目的:探究食管胃底静脉曲张出血内镜下套扎及组织胶注射术后再出血的危险因素。方法:选取2016年1月1日—2018年1月1日期间120例食管胃底静脉曲张出血内镜下套扎及组织胶注射术患者,随机分为观察组、对照组、联合组各40例,观察组术后给予普奈洛尔治疗,对照组术后予以单硝酸异山梨醇酯治疗,联合组予以普奈洛尔+单硝酸异山梨醇酯治疗;依据是否出现再出血情况将其分为有效止血组和再出血组,分析再出血的危险因素。结果:联合组再出血率显著低于观察组、对照组,差异具有统计学意义(P<0.05),三组药物成本效果分别为观察组:60.04,对照组:43.64,联合组:73.88;影响因素显示:AST、Child-Pugh B级、C级、腹水、静脉曲张血管数量>2支、脾切除术并分流术、曲张静脉内径为食管胃底静脉曲张患者早期再出血危险因素。结论:在开展内镜下套扎及组织胶注射术前,需尽量维系患者危险因素,降低再出血发生概率。
Objective: To investigate the risk factors of endoscopic ligation of esophageal and gastric varices bleeding and rebleeding after tissue injection. Methods: 120 patients with esophagogastric varices bleeding endoscopic ligation and tissue gel injection were selected from January 1, 2016 to January 1, 2018. They were randomly divided into observation group, control group and combined group. The observation group was treated with propranolol. The control group was treated with isosorbide mononitrate. And the combination group was treated with propranolol and isosorbide mononitrate. The patients were divided into two groups according to whether there was rebleeding. In the effective hemostatic group and the rebleeding group, risk factors for rebleeding were analyzed. Results: The rebleeding rate of the combined group was significantly lower than that of the observation group and the control group. The difference was statistically significant (P<0.05). The cost effects of the three groups were observed group: 60.04, control group: 43.64, combined group: 73.88;Influencing factors show that, AST, Child-Pugh grade B, C, ascites, varicose veins (>2), splenectomy and shunt, varicose vein inner diameter for esophagus Risk factors for early rebleeding in patients with fundal varices (P<0.05). Conclusion: Before endoscopic ligation and tissue injection, it is necessary to maintain the risk factors of patients and reduce the probability of rebleeding.
作者
陈云云
杨守东
CHEN Yun-yun;YANG Shou-dong(Department of Digestion 2, Fengcheng People's Hospital, Fengcheng Jiangxi 331100, China;Department of Pharmacy, Inner Mongolia BaogangHospital, Baotou Inner Mongolia 014010, China)
出处
《药品评价》
CAS
2019年第6期20-23,58,共5页
Drug Evaluation
